# Zhongshan Hengsai Biotechnology Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/zhongshan-hengsai-biotechnology-co

- Industry: Biotechnology
- Headquarters: Zhongshan, China
- Latest round: Series A (Nov 27, 2023)
- Investors on record: 3

## About

Based in Zhongshan, China, and established in 2022, Zhongshan Hengsai Biotechnology Co., Ltd. is a medical company that focuses on the research and development of tumor therapy vaccines. It was recognized as the National High-Tech Enterprise. Huining Liu, the founder and CEO of the company, graduated from Harvard Medical School and used to work for BMS and Quintiles. The company's R&D center and plant in Shanghai came into operation in 2021. In December 2025, Zhongshan Hengsai Biotechnology Co., Ltd. closed a strategic funding from new investor Tasly Holding Group.

The company is committed to developing individualized dendritic cell tumor therapeutic vaccines (DC vaccine). It constructed the Eco-DCVax platform for the development of DC vaccine products. Products within include therapeutic dendritic cell vaccine, which can be used in the treatment of lymphoma, chronic viral infections, autoimmune diseases, and chronic active EB virus infection.

The company generates revenue from providing biotechnology services.

## Funding rounds

- Series A, Nov 27, 2023 — Fuho Capital, Triwise Capital, Bison Capital

## Investors

- Fuho Capital (https://capitalatlas.ai/funds/fuho-capital) — Series A
- Triwise Capital (https://capitalatlas.ai/funds/triwise-capital) — Series A
- Bison Capital — Series A